MEGAN CASTILLO: Open Payments
NPI 1447781091 · SPRING, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,897 in 165 payments from 22 companies in 2025. Trend: 2023 $27 · 2024 $3,714 · 2025 $3,897
Food & beverage: $3,897
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 57 | $1,095 |
| Ipsen Biopharmaceuticals, Inc | 7 | $392 |
| Janssen Biotech, Inc. | 11 | $360 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $331 |
| Regeneron Healthcare Solutions, Inc. | 7 | $253 |
| Madrigal Pharmaceuticals | 11 | $225 |
| Ardelyx, Inc. | 6 | $196 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $170 |
| Aimmune Therapeutics, Inc. | 11 | $168 |
| Phathom Pharmaceuticals, Inc. | 6 | $133 |
Products named: RINVOQ, IQIRVO, DUPIXENT, TREMFYA, LINZESS, ENTYVIO, REZDIFFRA, SKYRIZI.
Industry payments across TX — which companies pay providers there.
